Episode 83: Did the Pharmaceutical Industry Suppress a Diabetes Cure?

Episode 83: Did the Pharmaceutical Industry Suppress a Diabetes Cure?

More than 500 million people worldwide live with diabetes. The global market for diabetes drugs and devices is worth hundreds of billions annually. A cured patient stops buying medication forever. Tonight we ask the question that millions of patients and their families have been asking for decades — and examine what the evidence in 2026 actually shows.

This episode explores:

* The insulin pricing scandal — a drug invented in 1921 that rose in price by over 1,000 percent between 1996 and 2019

* The structural incentive argument — why a one-time cure is financially less attractive than lifelong management

* The documented pattern of pharmaceutical companies spending more on marketing than research

* The 2025 and 2026 clinical trials — Vertex VX-880, Sana Biotechnology, Kriya Therapeutics — the closest humanity has ever come to a type 1 diabetes cure

* The deepfake cure scams that have exploited the conspiracy belief to defraud vulnerable patients

* The counter-argument — that the genuine scientific difficulty of curing diabetes explains the timeline without requiring deliberate suppression

For believers, the insulin pricing scandal and the decades of management-over-cure investment are the proof. For sceptics, the 2026 trial pipeline demonstrates that progress reflects scientific difficulty, not deliberate obstruction.

What is certain: the pharmaceutical industry made hundreds of billions from diabetes management. A cure that has been possible in theory for years is only now entering clinical trials.

Keywords: diabetes cure suppressed, pharmaceutical industry diabetes conspiracy, insulin price scandal, Big Pharma diabetes cover-up, type 1 diabetes cure 2026, Vertex VX-880 stem cell cure, diabetes treatment vs cure, pharmaceutical profit motive, insulin pricing truth, diabetes research suppressed